Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

Subjects:

Improvement effect of lactoferrin and Coenzyme Q10 on body composition of mice with sarcopenia. by Wenbin Wu (292223)

Subjects:

Enrichment analysis of genes from the significant MS module. by Lai Jiang (2401513)

Subjects:

Compression modulus of improved red clay at 1600 kPa. by Quan Shen (37564)

Subjects:

Compressive strain of improved red clay at 1600 kPa. by Quan Shen (37564)

Subjects:

<i>e-lgp</i> curve of improved red clay. by Quan Shen (37564)

Subjects:

<b>Manure improves temperature sensitivity of soil organic carbon by increasing soil alphaproteobacteria, phenols, and pH and decreasing soil esters</b> by Andong Cai (5237024)

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

EF-24 induces significant transcriptional changes in K-562 cells. by Ajeet P. Singh (22298432)

Subjects:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Among them, W₃BipY₈-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W₃BipY₈ but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W₃BipY₈. …”